patient

Guadecitabine Maintenance Therapy Shows Promise in High Risk MDS/AML Patients

Original Publication Date
Article Source
External Web Content
Guadecitabine (SGI-110), when given as maintenance therapy following allogeneic stem cell transplantation (allo-SCT), showed promising relapse-free survival rates (RFS) with manageable safety in high-risk patients with myelodysplastic syndromes/acute myeloid leukemia (MDS/AML)…

GTB-3550 TriKE Stimulates Natural Killer Cell Function in MDS and AML

Original Publication Date
Article Source
External Web Content
December 5, 2020 - GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia. GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk…

Oral Azacitidine Improves, Sustains Health-Related QoL in AML

Original Publication Date
Article Source
External Web Content
Treatment with the oral agent showed sustained health-related quality of life compared with placebo in patients with acute myeloid leukemia, according to results of the phase 3 QUAZAR AML-001 trial. Treatment with oral azacitidine (CC-486) showed sustained health-related quality…

Significant Racial, Ethnic Related Socioeconomic Disparities Influence Survival in AML

Original Publication Date
Article Source
External Web Content
Census tract socioeconomic status information demonstrated significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia AML in the Chicago metropolitan area. Significant disparities were found…

Beat AML Master Clinical Trial Showcases Paradigm Shift With Precision Medicine

Original Publication Date
Article Source
External Web Content
Delaying treatment for up to 7 days so that genomic data can be utilized to inform a personalized treatment approach is safe, feasible, and can improve overall survival in patients with acute myeloid leukemia. John C. Byrd, MD Delaying treatment for up to 7 days so that genomic…

Guang-Shing Cheng, M.D.

Institution
Fred Hutchinson Cancer Research Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Graft Versus Host Disease (GVHD)
About
Dr. Guang-Shing Cheng is Associate Professor in the Clinical Research Division at Fred Hutch in Seattle. Dr. Cheng is a pulmonologist who focuses on improving outcomes for cancer patients who have respiratory failure and lung complications related to their cancer treatments. She is developing new ways to prevent lung damage and improve lung function in these patients. Dr. Cheng’s main interest is bronchiolitis obliterans syndrome, a serious complication of blood stem cell transplantation. She also studies the role of respiratory viruses and other infectious pathogens in lung disease in
Subscribe to patient

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.